EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of Cationic Whey Protein Fraction in preventing common colds in children aged 3-7 years: A randomized, double-blind, placebo-controlled study

Wirksamkeit und Sicherheit der kationischen Molkenproteinfraktion zur Vorbeugung von Erkältungen bei Kindern im Alter von 3–7 Jahren: randomisierte, doppelblinde, placebokontrollierte Studie

Yue Wang, Aling Tang, Liping Shen, Yan Zhou, Ye Bi, Xiaojun Kuang, Wei Chen, Man Wang

Functional Foods in Health and Disease · 04.11.2026 · 16 (11) · 982-994

DOI: 10.31989/ffhd.v16i11.2131 ↗

Auf einen Blick

Bei gesunden Kindern im Alter von 3–7 Jahren reduzierte 200 mg IDP® täglich Häufigkeit und Dauer von Erkältungen. 50 mg zeigte kleinere, aber positive Effekte.

Fragestellung

Wirkt eine tägliche Supplementierung mit 50 mg oder 200 mg IDP® bei gesunden Kindern von 3–7 Jahren gegen Erkältungen und ist sie sicher?

Methode

Randomisierte, doppelblinde, placebokontrollierte Studie mit 350 gesunden Kindern im Alter von 3–7 Jahren; 1:1:1 zu 50 mg/Tag, 200 mg/Tag oder Placebo für 16 Wochen.

Ergebnisse

Nach 31 Dropouts umfasste die Auswertung 103, 107 und 109 Kinder. 200 mg IDP® reduzierte Häufigkeit und Dauer von Erkältungen signifikant. Beide Dosen waren gut verträglich.

Schlussfolgerung der Autor:innen

Die tägliche Supplementierung mit 200 mg IDP® ist laut Autor:innen eine wirksame und sichere Ernährungsstrategie zur Verringerung von Inzidenz und Dauer von Erkältungen.

Kernaussagen

  • 200 mg IDP® reduzierte Häufigkeit und Dauer von Erkältungen
  • 50 mg zeigte kleinere Effekte als 200 mg
  • Beide Dosen waren gut verträglich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Functional Foods in Health and Disease, online erschienen am 04.11.2026. Verfasst von Yue Wang und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Children are particularly susceptible to common cold due to their immature immune systems and frequent group exposures. A cationic whey protein fraction (IDP®) rich in lactoferrin, lactoperoxidase, and other bioactive peptides demonstrated immunomodulatory potential in preclinical studies, but clinical evidence in children is lacking.

Objective

To evaluate the efficacy and safety of daily supplementation with 50 mg or 200 mg of IDP® in reducing the frequency, duration, and severity of common colds in healthy children aged 3–7 years.

Methods

This randomized, double-blind, placebo-controlled study enrolled 350 healthy children aged 3–7 years (Registration number: ChiCTR2500114986). Participants were randomly assigned (1:1:1) to receive a standard IDP® dose (50 mg/day), an advanced IDP® dose (200 mg/day), or a placebo for 16 weeks. Parents completed weekly respiratory symptom questionnaires. The primary endpoints were the weekly frequency and duration of common cold episodes. Secondary endpoints included symptom severity, antibiotic use, absenteeism, and safety. Results and Discussion: After accounting for 31 dropouts, the final data set comprised 103, 107, and 109 children in the standard-dose, advanced-dose, and placebo groups, respectively. Daily supplementation with 200 mg IDP® significantly reduced the frequency and duration of common colds. Although the magnitude of benefit was smaller at 50 mg compared with 200 mg, the standard-dose group exhibited statistically and clinically relevant improvements relative to baseline and favorable trends compared to placebo, particularly in reducing cold frequency and duration during the early intervention period. Both doses of IDP® were well tolerated and had a favorable safety profile. Novelty: This clinical trial provides a novel insight into the effect of IDP® on the incidence and duration of common colds in children aged 3–7 years. The findings provide clinical evidence supporting the potential role of a cationic whey protein fraction as a nutritional intervention for respiratory health in children and provide preliminary evidence of a dose-dependent effect.

Conclusion

Daily supplementation with 200 mg of IDP® cationic whey protein fraction is an effective and safe nutritional strategy for reducing the incidence and duration of common colds in children, providing a practical approach to mitigating this widespread health burden. Keywords: cationic whey protein; children; common cold; symptom; safety; randomized controlled trial

Zitieren

APA

Wang, Y., Tang, A., Shen, L., Zhou, Y., Bi, Y., Kuang, X., Chen, W., & Wang, M. (2026). Efficacy and safety of Cationic Whey Protein Fraction in preventing common colds in children aged 3-7 years: A randomized, double-blind, placebo-controlled study. Functional Foods in Health and Disease, 16(11), 982-994. https://doi.org/10.31989/ffhd.v16i11.2131

Vancouver

Wang Y, Tang A, Shen L, Zhou Y, Bi Y, Kuang X, et al. Efficacy and safety of Cationic Whey Protein Fraction in preventing common colds in children aged 3-7 years: A randomized, double-blind, placebo-controlled study. Functional Foods in Health and Disease. 2026;16(11):982-994. doi:10.31989/ffhd.v16i11.2131

BibTeX
@article{Wang2026,
  author = {Wang, Yue and Tang, Aling and Shen, Liping and Zhou, Yan and Bi, Ye and Kuang, Xiaojun and Chen, Wei and Wang, Man},
  title = {Efficacy and safety of Cationic Whey Protein Fraction in preventing common colds in children aged 3-7 years: A randomized, double-blind, placebo-controlled study},
  journal = {Functional Foods in Health and Disease},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {982--994},
  doi = {10.31989/ffhd.v16i11.2131}
}
Kostenlos starten →